Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Public ClinicalTrials.gov record NCT02030067. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies
Study identification
- NCT ID
- NCT02030067
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Processa Pharmaceuticals
- Industry
- Enrollment
- 127 participants
Conditions and interventions
Conditions
Interventions
- RX-3117 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Jun 30, 2019
- Completion
- Nov 30, 2019
- Last update posted
- Dec 5, 2023
2013 – 2019
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rexahn Site | Birmingham | Alabama | 35294 | — |
| Rexahn Site | Tucson | Arizona | 85724 | — |
| Rexahn Site | Duarte | California | 91010 | — |
| Rexahn Site | Miami | Florida | 33136 | — |
| Rexahn Site | Miami Lakes | Florida | 33014 | — |
| Rexahn Site | Skokie | Illinois | 60077 | — |
| Rexahn Site | St Louis | Missouri | 63110 | — |
| Rexahn Site | Las Vegas | Nevada | 89119 | — |
| Rexahn Site | New York | New York | 10021 | — |
| Rexahn Site | San Antonio | Texas | 78229 | — |
| Rexahn Site | Salt Lake City | Utah | 84112 | — |
| Rexahn Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02030067, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02030067 live on ClinicalTrials.gov.